Brickell raises $8.9M on new common shares
BOULDER — Brickell Biotech Inc. (Nasdaq: BBI) raised $8.9 million after expenses on its sale of 26.3 million new common shares.
Shares priced at 38 cents, a roughly 25% discount on the stock’s closing price the day before shares were offered. Brickell stock traded recently at 40 cents. It had 86 million shares outstanding before the offering.
A U.S. Securities and Exchange Commission filing said proceeds will go to “research and development, including clinical trials, working capital, business development and general corporate purposes.”
SPONSORED CONTENT
Business Cares: April 2024
In Colorado, 1 in 3 women, 1 in 3 men and 1 in 2 transgender individuals will experience an attempted or completed sexual assault in their lifetime. During April, we recognize Sexual Assault Awareness Month with the hopes of increasing conversations about this very important issue.
Underwriters William Blair & Co. LLC and Oppenheimer & Co. Inc. can buy up to 4 million additional shares at a discount.
On Oct. 7, the company reported positive topline results in Phase 3 studies of its sofpironium bromide gel, which is said to inhibit receptors in certain glands to reduce excessive underarm sweat.
Brickell develops drugs for dermatologic and autoimmune diseases,
© BizWest Media LLC